Comment on “Cost Effectiveness of Vericiguat for the Treatment of Chronic Heart Failure with Reduced Ejection Fraction Following a Worsening Heart Failure Event from a US Medicare Perspective”
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1179-2027
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Comment on “Cost Effectiveness of Vericiguat for the Treatment of Chronic Heart Failure with Reduced Ejection Fraction Following a Worsening Heart Failure Event from a US Medicare Perspective” ; volume:40 ; number:9 ; day:19 ; month:7 ; year:2022 ; pages:929-930 ; date:9.2022
PharmacoEconomics ; 40, Heft 9 (19.7.2022), 929-930, 9.2022
- Creator
-
Gandjour, Afschin
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s40273-022-01170-6
- URN
-
urn:nbn:de:101:1-2022102602422914485800
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:23 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Gandjour, Afschin
- SpringerLink (Online service)
Other Objects (12)
Clinical and Economic Burden of Chronic Heart Failure and Reduced Ejection Fraction Following a Worsening Heart Failure Event
Cost Effectiveness of Vericiguat for the Treatment of Chronic Heart Failure with Reduced Ejection Fraction Following a Worsening Heart Failure Event from a US Medicare Perspective
Worsening effect of testosterone deficiency on males with heart failure with preserved ejection fraction
Vericiguat for Heart Failure with Reduced Ejection Fraction
Biomarkers in heart failure with preserved ejection fraction
Comorbidities in heart failure with preserved ejection fraction
Heart failure
Atrial fibrillation and risk of progressive heart failure in patients with preserved ejection fraction heart failure
Advance Care Planning (ACP) in Medicare Beneficiaries with Heart Failure
Animal models of heart failure with preserved ejection fraction
Heart Failure with Preserved Ejection Fraction—a Concise Review
SGLT2 inhibitors in heart failure with reduced ejection fraction
Clinical and Economic Burden of Chronic Heart Failure and Reduced Ejection Fraction Following a Worsening Heart Failure Event
Cost Effectiveness of Vericiguat for the Treatment of Chronic Heart Failure with Reduced Ejection Fraction Following a Worsening Heart Failure Event from a US Medicare Perspective
Worsening effect of testosterone deficiency on males with heart failure with preserved ejection fraction
Vericiguat for Heart Failure with Reduced Ejection Fraction
Biomarkers in heart failure with preserved ejection fraction
Comorbidities in heart failure with preserved ejection fraction
Heart failure
Atrial fibrillation and risk of progressive heart failure in patients with preserved ejection fraction heart failure
Advance Care Planning (ACP) in Medicare Beneficiaries with Heart Failure
Animal models of heart failure with preserved ejection fraction
Heart Failure with Preserved Ejection Fraction—a Concise Review
SGLT2 inhibitors in heart failure with reduced ejection fraction
Clinical and Economic Burden of Chronic Heart Failure and Reduced Ejection Fraction Following a Worsening Heart Failure Event
Cost Effectiveness of Vericiguat for the Treatment of Chronic Heart Failure with Reduced Ejection Fraction Following a Worsening Heart Failure Event from a US Medicare Perspective
Worsening effect of testosterone deficiency on males with heart failure with preserved ejection fraction
Vericiguat for Heart Failure with Reduced Ejection Fraction
Biomarkers in heart failure with preserved ejection fraction
Comorbidities in heart failure with preserved ejection fraction
Heart failure
Atrial fibrillation and risk of progressive heart failure in patients with preserved ejection fraction heart failure
Advance Care Planning (ACP) in Medicare Beneficiaries with Heart Failure
Animal models of heart failure with preserved ejection fraction
Heart Failure with Preserved Ejection Fraction—a Concise Review